492 related articles for article (PubMed ID: 30504675)
1. Recent Advances in Oligonucleotide-Based Therapy for Transthyretin Amyloidosis: Clinical Impact and Future Prospects.
Hayashi Y; Jono H
Biol Pharm Bull; 2018; 41(12):1737-1744. PubMed ID: 30504675
[TBL] [Abstract][Full Text] [Related]
2. Transthyretin (ATTR) amyloidosis: clinical spectrum, molecular pathogenesis and disease-modifying treatments.
Sekijima Y
J Neurol Neurosurg Psychiatry; 2015 Sep; 86(9):1036-43. PubMed ID: 25604431
[TBL] [Abstract][Full Text] [Related]
3. RNA-targeting and gene editing therapies for transthyretin amyloidosis.
Aimo A; Castiglione V; Rapezzi C; Franzini M; Panichella G; Vergaro G; Gillmore J; Fontana M; Passino C; Emdin M
Nat Rev Cardiol; 2022 Oct; 19(10):655-667. PubMed ID: 35322226
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic Oligonucleotides Targeting Liver Disease: TTR Amyloidosis.
Niemietz C; Chandhok G; Schmidt H
Molecules; 2015 Sep; 20(10):17944-75. PubMed ID: 26437390
[TBL] [Abstract][Full Text] [Related]
5. RNA Targeting and Gene Editing Strategies for Transthyretin Amyloidosis.
Ioannou A; Fontana M; Gillmore JD
BioDrugs; 2023 Mar; 37(2):127-142. PubMed ID: 36795354
[TBL] [Abstract][Full Text] [Related]
6. Liver-directed drugs for transthyretin-mediated amyloidosis.
Brannagan TH; Berk JL; Gillmore JD; Maurer MS; Waddington-Cruz M; Fontana M; Masri A; Obici L; Brambatti M; Baker BF; Hannan LA; Buchele G; Viney NJ; Coelho T; Nativi-Nicolau J
J Peripher Nerv Syst; 2022 Dec; 27(4):228-237. PubMed ID: 36345805
[TBL] [Abstract][Full Text] [Related]
7. Suppressing transthyretin production in mice, monkeys and humans using 2nd-Generation antisense oligonucleotides.
Ackermann EJ; Guo S; Benson MD; Booten S; Freier S; Hughes SG; Kim TW; Jesse Kwoh T; Matson J; Norris D; Yu R; Watt A; Monia BP
Amyloid; 2016 Sep; 23(3):148-157. PubMed ID: 27355239
[TBL] [Abstract][Full Text] [Related]
8. Recent progress in the understanding and treatment of transthyretin amyloidosis.
Sekijima Y
J Clin Pharm Ther; 2014 Jun; 39(3):225-33. PubMed ID: 24749898
[TBL] [Abstract][Full Text] [Related]
9. [Pathogenesis and therapy for transthyretin related amyloidosis].
Ando Y; Jono H
Rinsho Byori; 2008 Feb; 56(2):114-20. PubMed ID: 18402051
[TBL] [Abstract][Full Text] [Related]
10. Preclinical evaluation of RNAi as a treatment for transthyretin-mediated amyloidosis.
Butler JS; Chan A; Costelha S; Fishman S; Willoughby JL; Borland TD; Milstein S; Foster DJ; Gonçalves P; Chen Q; Qin J; Bettencourt BR; Sah DW; Alvarez R; Rajeev KG; Manoharan M; Fitzgerald K; Meyers RE; Nochur SV; Saraiva MJ; Zimmermann TS
Amyloid; 2016 Jun; 23(2):109-18. PubMed ID: 27033334
[TBL] [Abstract][Full Text] [Related]
11. Recent advances in transthyretin amyloidosis therapy.
Ueda M; Ando Y
Transl Neurodegener; 2014; 3():19. PubMed ID: 25228988
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of Therapeutic Oligonucleotides for Familial Amyloid Polyneuropathy in Patient-Derived Hepatocyte-Like Cells.
Niemietz CJ; Sauer V; Stella J; Fleischhauer L; Chandhok G; Guttmann S; Avsar Y; Guo S; Ackermann EJ; Gollob J; Monia BP; Zibert A; Schmidt HH
PLoS One; 2016; 11(9):e0161455. PubMed ID: 27584576
[TBL] [Abstract][Full Text] [Related]
13. Selective silencing of a mutant transthyretin allele by small interfering RNAs.
Kurosawa T; Igarashi S; Nishizawa M; Onodera O
Biochem Biophys Res Commun; 2005 Nov; 337(3):1012-8. PubMed ID: 16225852
[TBL] [Abstract][Full Text] [Related]
14. Tafamidis: a selective transthyretin stabilizer to treat wild-type ATTR amyloidosis and hereditary ATTR amyloidosis with cardiomyopathy.
Paton DM
Drugs Today (Barc); 2019 Dec; 55(12):727-734. PubMed ID: 31942875
[TBL] [Abstract][Full Text] [Related]
15. Effect of albumin on transthyretin and amyloidogenic transthyretin Val30Met disposition and tissue deposition in familial amyloidotic polyneuropathy.
Taguchi K; Jono H; Kugimiya-Taguchi T; Nagao S; Su Y; Yamasaki K; Mizuguchi M; Maruyama T; Ando Y; Otagiri M
Life Sci; 2013 Dec; 93(25-26):1017-22. PubMed ID: 24211615
[TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of a TTR specific antisense oligonucleotide in patients with transthyretin amyloid cardiomyopathy.
Benson MD; Dasgupta NR; Rissing SM; Smith J; Feigenbaum H
Amyloid; 2017 Dec; 24(4):219-225. PubMed ID: 28906150
[TBL] [Abstract][Full Text] [Related]
17. A Review of Novel Agents and Clinical Considerations in Patients With ATTR Cardiac Amyloidosis.
Benbrahim M; Norman K; Sanchorawala V; Siddiqi OK; Hughes D
J Cardiovasc Pharmacol; 2021 May; 77(5):544-548. PubMed ID: 33657048
[TBL] [Abstract][Full Text] [Related]
18. TTR gene silencing therapy in post liver transplant hereditary ATTR amyloidosis patients.
Moshe-Lilie O; Dimitrova D; Heitner SB; Brannagan TH; Zivkovic S; Hanna M; Masri A; Polydefkis M; Berk JL; Gertz MA; Karam C
Amyloid; 2020 Dec; 27(4):250-253. PubMed ID: 32578459
[TBL] [Abstract][Full Text] [Related]
19. [Application to transthyretin analysis].
Ueda M; Ando Y
Rinsho Byori; 2006 Jun; 54(6):601-8. PubMed ID: 16872010
[TBL] [Abstract][Full Text] [Related]
20. Inotersen (transthyretin-specific antisense oligonucleotide) for treatment of transthyretin amyloidosis.
Benson MD; Dasgupta NR; Monia BP
Neurodegener Dis Manag; 2019 Feb; 9(1):25-30. PubMed ID: 30561247
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
